title: The DNA binding domain of p53 is sufficient to trigger a potent apoptotic response at the mitochondria.
abstract: The tumor suppressor p53 is one of the most studied proteins in human cancer.1-3 While nuclear p53 has been utilized for cancer gene therapy, mitochondrial targeting of p53 has not been fully exploited to date.4,5 In response to cellular stress, p53 translocates to the mitochondria and directly interacts with Bcl-2 family proteins including antiapoptotic Bcl-XL and Bcl-2 and proapoptotic Bak and Bax.6 Antiapoptotic Bcl-XL forms inhibitory complexes with proapoptotic Bak and Bax preventing their homo-oligomerization.7 Upon translocation to the mitochondria, p53 binds to Bcl-XL, releases Bak and Bax from the inhibitory complex and enhances their homo-oligomerization.8 Bak and Bax homotetramer formation disrupts the mitochondrial outer membrane, releases antiapoptotic factors such as cytochrome c and triggers a rapid apoptotic response mediated by caspase induction.9 It is still unclear if the MDM2 binding domain (MBD), the proline-rich domain (PRD) and/or DNA binding domain (DBD) of p53 are the domains responsible for interaction with Bcl-XL.10-17 The purpose of this work is to determine if a smaller functional domain of p53 is capable of inducing apoptosis similarly to full length p53. To explore this question, different domains of p53 (MBD, PRD, DBD) were fused to the mitochondrial targeting signal (MTS) from Bcl-XL to ensure Bcl-XL specific targeting.18 The designed constructs were tested for apoptotic activity (TUNEL, Annexin-V, and 7-AAD) in 3 different breast cancer cell lines (T47D, MCF-7, MDA-MB-231), in a cervical cancer cell line (HeLa) and in non-small cell lung adenocarcinoma cells H1373. Our results indicate that DBD-XL (p53 DBD fused to the Bcl-XL MTS) reproduces (in T47D cells) or demonstrates increased apoptotic activity (in MCF-7, MDA-MB-231, and HeLa cells) compared to p53-XL (full length p53 fused to Bcl-XL MTS). Additionally, mitochondrial dependent apoptosis assays (TMRE, caspase-9), co-IP and overexpression of Bcl-XL in T47D cells suggest that DBD fused to XL MTS may bind to and inhibit Bcl-XL. Taken together, our data demonstrates for the first time that the DBD of p53 may be the minimally necessary domain for achieving apoptosis at the mitochondria in multiple cell lines. This work highlights the role of small functional domains of p53 as a novel cancer biologic therapy.
authors: Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah , Utah 84112, United States.
authors: Karina J
authors: KJ
authors: Matissek
authors: Mohanad
authors: M
authors: Mossalam
authors: Abood
authors: A
authors: Okal
authors: Carol S
authors: CS
authors: Lim
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000502:physiology; D045744:Cell Line, Tumor; D006801:Humans; D047468:Immunoprecipitation; D020287:In Situ Nick-End Labeling; D051379:Mice; D008928:Mitochondria / Q000378:metabolism*; D017434:Protein Structure, Tertiary; D016159:Tumor Suppressor Protein p53 / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D051020:bcl-X Protein / Q000235:genetics / Q000378:metabolism
chemical_list: D016159:Tumor Suppressor Protein p53; D051020:bcl-X Protein
references: Cancer Res. 2004 Apr 1;64(7):2350-6
references: 15059885
references: J Virol. 1998 Dec;72(12):9479-90
references: 9811681
references: Cell. 2008 Aug 8;134(3):451-60
references: 18692468
references: Exp Hematol. 2002 Sep;30(9):982-9
references: 12225789
references: Mol Pharm. 2012 Nov 5;9(11):3318-29
references: 22957899
references: J Hum Genet. 2004;49(3):134-140
references: 14986171
references: Mol Pharm. 2013 Apr 1;10(4):1340-9
references: 23398638
references: J Neurosci. 1999 Sep 1;19(17):7394-404
references: 10460246
references: Ther Deliv. 2012 Aug;3(8):961-79
references: 22946430
references: J Mol Med (Berl). 2011 Mar;89(3):237-45
references: 21340684
references: Nat Rev Mol Cell Biol. 2010 Sep;11(9):655-67
references: 20729931
references: Cancer Res. 2011 Jul 1;71(13):4518-26
references: 21546570
references: Pharm Res. 2012 Aug;29(8):2317-28
references: 22549737
references: Mol Pharm. 2012 May 7;9(5):1449-58
references: 22380534
references: Cytometry. 1992;13(2):204-8
references: 1547670
references: J Cell Biol. 2003 Jan 6;160(1):65-75
references: 12515825
references: J Biol Chem. 2006 Mar 31;281(13):8600-6
references: 16443602
references: Trends Mol Med. 2007 May;13(5):192-9
references: 17383232
references: Science. 2011 Nov 25;334(6059):1129-33
references: 22033517
references: J Biol Chem. 2011 Aug 5;286(31):27751-60
references: 21659527
references: Comp Biochem Physiol B Biochem Mol Biol. 2008 Sep;151(1):10-27
references: 18602321
references: Pharm Res. 2011 Dec;28(12):3256-64
references: 21710341
references: Biochem Biophys Res Commun. 2006 Mar 24;341(4):938-44
references: 16455050
references: Biophys J. 2003 Nov;85(5):3350-7
references: 14581236
references: Hum Gene Ther. 2005 Sep;16(9):1016-27
references: 16149900
references: Mol Cell. 2003 Mar;11(3):577-90
references: 12667443
references: FEBS Lett. 2004 Feb 13;559(1-3):171-4
references: 14960327
references: Ther Deliv. 2010 Jul;1(1):169-93
references: 21113240
references: Cancer Cell. 2003 Nov;4(5):371-81
references: 14667504
references: Nature. 1989 Dec 7;342(6250):705-8
references: 2531845
references: Science. 2006 Nov 24;314(5803):1233
references: 17124301
references: Oncogene. 1992 Apr;7(4):743-9
references: 1565469
references: Biophys J. 2004 Jun;86(6):3993-4003
references: 15189895
references: J Immunol Methods. 2005 Nov 30;306(1-2):68-79
references: 16256133
references: Br J Cancer. 2002 Oct 7;87(8):909-17
references: 12373608
references: Cold Spring Harb Perspect Biol. 2010 Jun;2(6):a000919
references: 20516128
references: PLoS One. 2011;6(10):e26014
references: 22039431
references: Mol Cell. 2006 Apr 21;22(2):259-68
references: 16630893
references: Cancer Sci. 2004 Aug;95(8):662-5
references: 15298729
references: Nat Rev Drug Discov. 2006 Jul;5(7):596-613
references: 16816840
references: Cancer Res. 2009 Jan 1;69(1):219-26
references: 19118006
references: J Biol Chem. 2010 Jan 29;285(5):3439-50
references: 19955567
references: Mol Pharm. 2012 Jan 1;9(1):187-95
references: 22136227
references: J Immunol Methods. 1995 Jul 17;184(1):39-51
references: 7622868
references: Methods Cell Biol. 1998;57:251-64
references: 9648109
references: J Pathol. 2011 Jan;223(2):116-26
references: 21125670
references: J Microsc. 2006 Dec;224(Pt 3):213-32
references: 17210054
references: Oncogene. 1990 Jun;5(6):893-9
references: 1694291
references: Jpn J Cancer Res. 2002 May;93(5):559-66
references: 12036452
references: J Am Chem Soc. 2011 Feb 9;133(5):1244-7
references: 21210687
references: J Biol Chem. 1984 May 25;259(10):6571-4
references: 6327685
references: Nat Cell Biol. 2004 May;6(5):386-8
references: 15122264
references: Cell. 2006 Dec 29;127(7):1323-34
references: 17182091
references: Hum Cell. 2002 Mar;15(1):1-12
references: 12126059
references: J Neurosci Methods. 2005 Jul 15;146(1):42-9
references: 15935219
references: Cell. 2004 Jan 23;116(2):235-46
references: 14744434
references: Science. 1995 Mar 10;267(5203):1498-502
references: 7878469
references: J Control Release. 2009 Dec 16;140(3):245-9
references: 19576252
references: Nature. 1997 May 15;387(6630):296-9
references: 9153395
references: Biochim Biophys Acta. 2009 May;1787(5):414-20
references: 19007744
references: Cytometry A. 2010 Aug;77(8):733-42
references: 20653013
references: Cell Cycle. 2008 Aug 15;7(16):2584-90
references: 18719383
references: Cell. 2006 Jul 14;126(1):107-20
references: 16839880